Dr. Ehsan Sadri, MD

Dr. Sadri practices at Newport Beach Surgery Center in Newport Beach, California.

Dr. Sadri's NPI, 1114025780, was assigned on September 20, 2006. Dr. Sadri graduated from University Of Michigan Medical School in 2000. Dr. Sadri holds California license A87053.

Dr. Sadri's primary practice is Newport Beach Surgery Center, at 361 Hospital Road, Suite 124, Newport Beach, CA 92663. The practice phone is (949) 631-0988.

Dr. Sadri's primary practice is Newport Beach Surgery Center in Newport Beach, California. Dmand AI also links Dr. Sadri to 1 physician office and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sadri practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Sadri's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Sadri is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Sadri is licensed in California.

Dmand AI lists cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation and glaucoma among the conditions Dr. Sadri treats.

CMS data shows 1,092 Medicare services from Dr. Sadri across 17 procedure codes in 2024, for 303 Medicare patients. Medicare paid $113,647 for them.

CMS counts 303 Medicare patients who saw Dr. Sadri in 2024. The largest group is 65 to 74, with 144 patients. 75% of them have high cholesterol, and 69% have high blood pressure. 35% are also on Medicaid. Their average risk score is 1.15, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Sadri's median patient age at 67, with 58% women.

In 2024, Dr. Sadri wrote 3,234 Medicare Part D claims for 714 patients. 59% of them were for generic drugs. CMS names the drug for 3,151 of them, across 33 drugs with 11 or more claims each, at $280,720 in total drug cost. In 2023, CMS named 2,643 claims across 29 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 70 out of 100 for Dr. Sadri for performance year 2024, reported individually. Dr. Sadri accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 94 procedures of cataract surgery by Dr. Sadri, more than 73% of the clinicians it reports for that procedure.

Dmand AI links 10 papers to Dr. Sadri, published from 2011 to 2025. 2024 was the busiest year, with 3. The most frequent topics are Ophthalmic Solutions. Dr. Sadri has published most often in Clin Ophthalmol. Dr. Sadri's most frequent co-authors are Gregg Jonathan Berdy, MD, Julio C. Echegoyen, MD, PhD and Gregory D. Parkhurst, MD.

Dmand AI links Dr. Sadri to 8 clinical trials, 2 of them phase 2/3 studies. 1 is still active or recruiting. Conditions studied include Eyelid Diseases, Blepharitis and Dry Eye Syndromes. Tarsus Pharmaceuticals, Inc. sponsors the most, 3.

CMS Open Payments shows 1,148 general payments to Dr. Sadri from 41 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 40% of the total. Johnson & Johnson Surgical Vision, Inc. paid the most, $98,945. It also lists 4 research payments totaling $16,036 from 2016 to 2025.

Dmand AI lists 1 award for Dr. Sadri.

Dr. Sadri graduated from University Of Michigan Medical School in 2000. Dr. Sadri is a member of AAO, AMA and ASCRS.

Dr. Sadri is in network with 12 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.